SandboxAQ And MapLight Therapeutics Collaborate To Discover And Develop Therapies Targeting G Protein-Coupled Receptor For Treatment Of Central Nervous System Disorders

SandboxAQ and MapLight Therapeutics, Inc. (NASDAQ:MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders.

Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, development, regulatory, and commercial milestone payments of up to $200 million in aggregate. The companies will jointly conduct preclinical research activities and MapLight will have exclusive rights for potential clinical development and commercialization of collaboration compounds.